The Impact of the Use of Symbiotics in the Progression of Nonalcoholic Fatty Liver Disease in a Rat Model

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by accumulation of intrahepatic lipid. The use of live microorganisms promotes beneficial effects; however, the use of symbiotic and its role in NAFLD is not yet fully understood. Aim:Verify if the symbiotic administration influences the occurrence and progression of NAFLD in rats, after induction of hepatic steatosis by high calorie diet. Method: Forty-five rats were divided into four groups: G1 (control); G2 (control+symbiotic); G3 (high calorie+symbiotic) and G4 (high calorie), and euthanized after 60 days of diet. Liver disease was evaluated by biochemical analysis, IL6 measurement and histological assessment. Results: Symbiotic had influence neither on weight gain, nor on coefficient dietary intake in G3 and G4. G2 had the greatest weight gain, while G1 had the highest coefficient dietary intake between groups. G1 showed higher expression of aspartate aminotransferase than those from G2 (150±35 mg/dl, and 75±5 mg/dl) while G4 showed higher expression of the enzyme compared to G3 (141±9.7 mg/dl to 78±4 mg/dl). Liver histology showed different stages of NAFLD between groups. G4 animals showed increased serum interleukin-6 when compared to G3 (240.58±53.68 mg/dl and 104.0±15.31 mg/dl). Conclusion: Symbiotic can reduce hepatic aminotransferases and interleukin-6 expression. However, the histology showed that the symbiotic was not able to prevent the severity of NAFLD in rats.

Effect of Probiotic Oral Administration on Skin Wound Healing in Rats

“…A total of 72 adult male Wistar rats weighing +250 g obtained from the Positivo University laboratory were used. The rats were weighed and divided into two groups with 36 animals each, one control which received maltodextrin 250 mg/day) and one probiotic group supplemented with a probiotic Probiatop ® from FQM-FARMA compound that contained Lactobacillus paracasei LPC-37, Bifidobacterium lactis HN0019, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM ® , at the dose of 250 mg/day, which corresponds to the approximate dose of 200,000 to 210,000 CFU (colony forming units), administered orally once a day, starting five days before surgery until the euthanasia day, with the aid of a spatula 24 mixed in cream cheese. The two groups were subsequently divided into three subgroups according to the moment of the euthanasia in the 3 rd postoperative (3PO) day; 7 th postoperative (7PO) day and 10 th postoperative (10PO) day, with 12 rats each.…”

“…The manipulation of the healing process with the use of probiotics has been studied both by topical application as well as by oral use. Probiotics are defined by the World Health Organization as “live microorganisms that when given in adequate amounts, confer a health benefit to the host 8 , 24 , 26 , 29 . Probiotics have been associated with improved healing of intestinal ulcers and healing of cutaneous wounds, among other actions already described in the literature 20 .…”

Nutrição Na Doença Hepática Gordurosa Não Alcoólica E Síndrome Metabólica: Uma Revisão Integrativa

“…Logo, destaca-se a relevância desta comorbidade em pacientes com DHGNA e SM. Tarantino et al (2007) estimaram que a DHGNA atinge 57,5% a 74% da população obesa de vários países do mundo. Também, Schild, Santos e Alves (2013) no estudo que realizaram observaram que 50% dos pacientes submetidos à cirurgia bariátrica apresentam DHGNA.…”

“…Desta forma, estão indicados na prevenção e no tratamento da DHGNA (ZHAO et al, 2004). Também, Tagliari et al (2017) num estudo com ratos observaram que os simbióticos podem reduzir as aminotransferases hepáticas e a expressão da interleucina-6. No entanto, a histologia mostrou que os simbióticos não conseguiram prevenir a gravidade da DHG-NA em ratos.…”

The Therapeutic Impact of Probiotics on Nonalcoholic Fatty Liver Disease in Pediatrics: A Systematic Review

“…In addition to traditional therapeutic options, experimental studies indicate that the use of prebiotics, probiotics and symbiotics in the modulation of the intestinal microbiota proved beneficial in the treatment of obesity and NAFLD. 14 , 15 , 16 , 17 , 18 However, some scientific societies argue that the number of evidence strains on probiotic treatments is poor and further studies are needed in the population to understand their risks and benefits in a greater number of individuals. 19 Similarly, there is no indication that they have been used in the latest evidence-based treatment algorithms from leading specialized societies around the world.…”